



## NASP 2023 Annual Meeting & Expo Universal Activity Number

### Monday, September 18

#### Accreditation

Accreditation Program Offerings & Updates	0016-9999-23-113-L04-P
Building Blocks of Accreditation 2.0	0016-9999-23-124-L04-P
Keys to Maintaining Specialty Accreditation	0016-9999-23-127-L04-P
Deeper Dive into Accreditation Standards: Rotating Roundtable Discussions	0016-9999-23-129-L04-P
Preparing Your Team for an Accreditation Survey & How to Promote a Work-Life Balance	0016-9999-23-138-L04-P
Do You Manage Your Accreditation Project or Does it Manage You?	0016-9999-23-140-L04-P
Common Deficiencies & Strategies to Overcome: Panel Discussion	0016-9999-23-144-L04-P

#### CSP Prep Course

Inflammatory Diseases	0016-9999-23-111-L01-P
Hepatitis	0016-9999-23-121-L01-P
Oncology & Hematology	0016-9999-23-125-L01-P
Neurology (Parkinson's Disease, Huntington's Disease, Tardive Dyskinesia, Seizure and MS)	0016-9999-23-133-L01-P
Operations Part 1 and 2	0016-9999-23-137-L04-P
Pulmonary (Asthma, Pulmonary Arterial Hypertension, Pulmonary Fibrosis and Cystic Fibrosis)	0016-9999-23-143-L01-P

#### Home Infusion

Home Infusion: Where Do I Begin?	0016-9999-23-116-L01-P
Building a Foundation for Home Infusion Revenue Cycle	0016-9999-23-118-L04-P
Accreditation? What I Need to Know	0016-9999-23-122-L04-P
How Does it All Add Up: Getting Payment for Home Infusion Services	0016-9999-23-128-L04-P



## NASP 2023 Annual Meeting & Expo Universal Activity Number

### Hospital/Health System Specialty Pharmacy

A Practical Guide to Designing, Creating & Using Data Driven Patient Monitoring Tools	0016-9999-23-117-L04-P
Approaches to Improving Health Equity & Patient Affordability: Panel Discussion & Breakout	0016-9999-23-123-L04-P
Elevating the Practice of Care Coordination for All Stakeholders	0016-9999-23-130-L04-P
Winning Tactics for Integrating Specialty, Ambulatory Infusion & Home Infusion Pharmacy	0016-9999-23-136-L04-P
Payor Partnerships: Where Outcomes, Value & Data Meet	0016-9999-23-141-L04-P
Future Directions for Health System Specialty Pharmacies: 340B Updates, Opportunities & Challenges	0016-9999-23-145-L04-P

### Specialty Pharmacy Law

Specialty Pharmacies & PBMs - A Transformational Year to Remember	0016-9999-23-112-L03-P
Fraud, Waste, and Abuse, She Wrote	0016-9999-23-119-L03-P
Working Collaboratively with Physicians in the Infusion Space	0016-9999-23-126-L01-P
Preserving the Trust: Protecting the Security, Privacy & Unauthorized Use of Your Pharmacy's Data	0016-9999-23-131-L03-P
More than Checking the Box: Key Due Diligence Topics & Techniques in the Specialty Pharmacy Space	0016-9999-23-135-L03-P
Update on FDA Issues	0016-9999-23-142-L03-P
Issues Pertaining to Shared Services & Central Fill Arrangements	0016-9999-23-146-L03-P



## NASP 2023 Annual Meeting & Expo Universal Activity Number

### Technology

Technology Workshop – All Sessions	0016-9999-23-114-L04-P
------------------------------------	------------------------

### Tuesday, September 19

Building the Modern Specialty Pharmacy Experience: A Technology Wishlist from the Front Lines	0016-9999-23-066-L04-P
Impacting Rare Disease Patient Outcomes through Innovation	0016-9999-23-067-L01-P
NASP in Action - State & Federal Efforts & Wins	0016-9999-23-068-L03-P
Specialty Medication Pipeline 2023	0016-9999-23-069-L01-P 0016-9999-23-069-L01-T
Biosimilar Series: Introduction to the US Biosimilar Market	0016-9999-23-071-L01-P 0016-9999-23-071-L01-T
Developing a Cybersecurity Strategy for Specialty Pharmacy	0016-9999-23-072-L04-P
It's More Than Just a Chat	0016-9999-23-070-L04-P
Regulator & Dispenser Preparation for DSCSA	0016-9999-23-073-L03-P
Clinical Quality & Specialty Pharmacists: Improving Patient Care	0016-9999-23-074-L05-P
NASP Customer Experience White Paper Presentation	0016-9999-23-075-L04-P
Patient Assistance Program Panel Discussion - Challenges & Opportunities for Specialty Pharmacies	0016-9999-23-076-L04-P 0016-9999-23-076-L04-T
The Foundation of Your Specialty Pharmacy's Success: Your Leadership Team	0016-9999-23-077-L04-P
Alternative Funding Programs Impact and Unintended Consequences: Multi-Stakeholder Perspectives	0016-9999-23-078-L04-P 0016-9999-23-078-L04-T
Collaborative Arrangements with Physicians, Hospitals & Other Referral Sources	0016-9999-23-079-L03-P
Gene & Cell Therapy: A Review of Current & Future Treatments	0016-9999-23-080-L01-P
The Expanding Role of Data in Specialty Patient Management & Cost of Care	0016-9999-23-081-L04-P



## NASP 2023 Annual Meeting & Expo Universal Activity Number

### Wednesday, September 20

2023 Oncology Market Trends and Pipeline Update	0016-9999-23-083-L01-P 0016-9999-23-083-L01-T
Healthcare Trends in Dallas	0016-9999-23-082-L99-P
Reimagining Pharmacy Financing	0016-9999-23-084-L04-P
The 340B Drug Pricing Program: Point/Counterpoint	0016-9999-23-085-L03-P
Biosimilar Series: Switch Policies & Implications for Patients & Practice - The Canadian Experience	0016-9999-23-086-L01-P
Exploring Illegal Constraints on Trade in the Pharmaceutical Supply Chain	0016-9999-23-089-L04-P 0016-9999-23-089-L04-T
Key Adherence Metrics: Persistency & PDC	0016-9999-23-087-L04-P
Meeting Special Patient Needs - Understanding Invisible Disabilities	0016-9999-23-088-L04-P
2023 US Specialty Pharmaceutical Trends, Issues and Outlook	0016-9999-23-090-L04-P 0016-9999-23-090-L04-T
ISMP Proactive Risk Assessments for Specialty Pharmacy: Play it Safe!	0016-9999-23-091-L05-P
Managing Rare Disease Therapies within an Integrated Health System Specialty Pharmacy	0016-9999-23-092-L01-P
New Drug Update 2023	0016-9999-23-093-L01-P 0016-9999-23-093-L01-T
The Inflation Reduction Act: What We Know and What We Don't Know	0016-9999-23-098-L03-P

### Thursday, September 21

Biosimilar Series: Dual WAC Pricing Strategy: Creating Market Choice or Market Chaos?	0016-9999-23-106-L01-P
Biosimilar Series: Spearheading Biosimilar Adoption & Implementation in Clinical Practice	0016-9999-23-102-L01-P
Combating Health Inequities: How Specialty Pharmacies Can Address Social Determinants of Health	0016-9999-23-094-L04-P
Establishing Home Infusion Pharmacy in a Health System	0016-9999-23-103-L04-P
Leveraging Specialty Pharmacy to Support Population Health Initiatives	0016-9999-23-107-L04-P
NASP Leadership - Federal Efforts to Address DIR Reform and Patient Access to Specialty Pharmacies	0016-9999-23-110-L03-P



## NASP 2023 Annual Meeting & Expo Universal Activity Number

Pharmacological Advancements in Atopic Dermatitis	0016-9999-23-095-L01-P
Pharmacy Benefit Manager (PBM) Network Access & Audit Trends	0016-9999-23-096-L04-P 0016-9999-23-096-L04-T
Pharmacy Reimbursement for Every Order & the Prevention of Costly Write-Offs	0016-9999-23-104-L04-P
Prescription Digital Therapeutics Pipeline 2023	0016-9999-23-097-L01-P
Specialty DeLIVERy: Hot Topics in Liver Disease	0016-9999-23-099-L01-P
Specialty Pharmacy Technology Enabling Solutions	0016-9999-23-100-L04-P
State of Care: Transplant	0016-9999-23-108-L01-P
The Impact of the Inflation Reduction Act on Patient Assistance Programs	0016-9999-23-101-L03-P 0016-9999-23-101-L03-T
The Right Drug to the Right Patient: The Value of Pharmacogenomics in Precision Medicine	0016-9999-23-109-L05-P
The S.M.A.R.T. Approach to Integrative Therapy Using (RA) Patient-Centered Goals	0016-9999-23-105-L01-P

### Posters

Group 1 Quality of Care	0016-9999-23-120-H04-P
Group 2 Clinical or Diagnosis-Related Patient Outcomes	0016-9999-23-132-H04-P
Group 3 Clinical or Diagnosis-Related Patient Outcomes	0016-9999-23-134-H01-P
Group 4 Financial or Cost-Related Outcomes	0016-9999-23-139-H04-P
Group 5 Digital Engagement/Technology in Specialty Pharmacy Services	0016-9999-23-147-H05-P
Group 6 Pharmacist driven Clinical Interventions	0016-9999-23-148-H04-P
Group 7 Specialty Pharmacy topics	0016-9999-23-149-H04-P